Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Adventures in targeting.

Theresa M Allen1, Puja Sapra, Elaine Moase

  • 1Department of Pharmacology, University of Alberta, Edmonton, Alberta, T6G 2H7, Canada. terry.allen@ualberta.ca

Journal of Liposome Research
|February 27, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Targeting genomic instability in cancer.

Cell·2026
Same author

Derivation of AZD5335, a Novel FRα-Targeted TOP1i-Loaded ADC, for the Treatment of FRα-Expressing Cancers.

Clinical cancer research : an official journal of the American Association for Cancer Research·2025
Same author

A Novel B7-H4xCD3 Bispecific T-cell Engager (PF-07260437) Synergizes with Breast Cancer Standard of Care and Immune Checkpoint Therapies.

Molecular cancer therapeutics·2025
Same author

Cross-Cultural Adaptation and Validation of the Person-Centered Therapeutic Relationship in Physiotherapy Scale to European Portuguese.

Healthcare (Basel, Switzerland)·2024
Same author

Higher frequency of gastric neoplasia in advanced chronic liver disease patients: Impact of screening endoscopy in an intermediate-high risk country.

Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver·2024
Same author

Mediation of antitumor activity by AZD4820 oncolytic vaccinia virus encoding IL-12.

Molecular therapy. Oncology·2024

This study guides the rational use of immunoliposomal anticancer drugs by evaluating ligand choice and model systems. Optimized immunoliposome design enhances drug delivery and therapeutic efficacy in various cancer models.

Area of Science:

  • Biotechnology
  • Nanomedicine
  • Oncology

Background:

  • Immunoliposomes offer targeted drug delivery for cancer therapy.
  • Optimizing ligand selection and formulation is crucial for efficacy.

Purpose of the Study:

  • To provide guidance on the rational design and application of immunoliposomal anticancer drugs.
  • To evaluate the impact of ligand choice and model systems on immunoliposome performance.

Main Methods:

  • In vitro and in vivo studies using various model systems (hematological malignancies, solid tumors).
  • Evaluation of different coupling techniques (e.g., Mal-PEG-DSPE) for antibody attachment.
  • Pharmacokinetic analysis of immunoliposome circulation half-lives.
  • Comparison of therapeutic efficacy across different immunoliposome formulations.

Related Experiment Videos

Main Results:

  • Targeted liposomes showed significantly higher binding and cytotoxicity in vitro.
  • Immunoliposome clearance rates varied based on coupling methods; Fc-region-masked methods improved circulation.
  • Post-insertion methods yielded immunoliposomes with comparable efficacy to conventional methods.
  • Successful in vivo targeting was achieved with accessible targets, longer circulation times, and internalizing epitopes.

Conclusions:

  • Rational design of immunoliposomal drugs requires careful consideration of ligand, coupling method, and target accessibility.
  • Optimized immunoliposomes demonstrate improved pharmacokinetic profiles and therapeutic efficacy in preclinical cancer models.